Data as of Oct 24
| +0.11 / +1.07%|
The 6 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 24.00, with a high estimate of 38.00 and a low estimate of 17.00. The median estimate represents a +130.33% increase from the last price of 10.42.
The current consensus among 7 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.